BCL2 and neoplasm: Venetoclax can selectively target to inhibit BCL2, restore the apoptotic process, replace pro-apoptotic proteins, and impart cytotoxicity on BCL2-overexpressed tumor cells [21,22], ultimately contributing to the killing of tumor cells [23].